Zoetis Inc. (NYSE:ZTS) Shares Purchased by TIAA Trust National Association

TIAA Trust National Association lifted its position in Zoetis Inc. (NYSE:ZTS) by 17.3% in the 1st quarter, HoldingsChannel.com reports. The firm owned 117,215 shares of the company’s stock after acquiring an additional 17,258 shares during the quarter. TIAA Trust National Association’s holdings in Zoetis were worth $19,834,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Hohimer Wealth Management LLC raised its position in Zoetis by 1.2% during the fourth quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock worth $866,000 after acquiring an additional 52 shares during the period. Forum Financial Management LP raised its position in Zoetis by 0.8% during the fourth quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock worth $1,458,000 after acquiring an additional 56 shares during the period. Angeles Wealth Management LLC raised its position in Zoetis by 3.5% during the fourth quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after acquiring an additional 56 shares during the period. Prossimo Advisors LLC raised its position in Zoetis by 1.7% during the fourth quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after acquiring an additional 57 shares during the period. Finally, River Street Advisors LLC raised its position in Zoetis by 3.4% during the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after acquiring an additional 58 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 0.4 %

Shares of NYSE:ZTS traded down $0.65 during trading on Friday, hitting $178.58. 2,131,427 shares of the company were exchanged, compared to its average volume of 2,211,473. The stock has a market capitalization of $81.49 billion, a P/E ratio of 34.41, a PEG ratio of 2.77 and a beta of 0.86. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The firm’s 50 day moving average price is $173.66 and its 200-day moving average price is $176.67.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The business had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.31 EPS. On average, research analysts predict that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be issued a $0.432 dividend. The ex-dividend date is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.97%. Zoetis’s payout ratio is 33.33%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research analyst reports. Piper Sandler restated an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. HSBC dropped their target price on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Barclays dropped their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Stifel Nicolaus dropped their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. Finally, The Goldman Sachs Group dropped their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday, May 6th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $211.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.